Scancell Share Discussion Threads

[inanaco] 18/4/2023 16:58

Panama7 fresh off a snooker table ...

[panama7] 18/4/2023 14:18

Where are all the happy clappers who have been ramping this to the high heavens for the last month. Once again always the bridesmaid never the bride. Seagen 43bn, Prometheus 11bn, Scancell zero BN. Whatever happened to Scib , in a previous RNS they stated first results due by end of 2022, third of the way through the year and nothing to report. RG leaves THE MOST EXCITING BIOTECH in the UK to join ONE OF THE MOST EXCITING and all just when the serendipitous discovery of Moditope goes on trial. I wonder if it's not living up to it's billing, it would appear Goodfellow thinks so, he is obviously not relying on Scancell for his big retirement payout, a serious red Flag.

[golcheja] 18/4/2023 10:36

Personally the poster looks like a storm in a tea cup. All yesterday news repeat on what was published what is the point I ask and so ask the market with 18p at the bottom line.

[marcusl2] 18/4/2023 09:48

Scancell
@scancellpharma
·
1m
Excited to be presenting a poster about our ModiFY phase I/II basket clinical trial at #AACR23. Find us at:

[golcheja] 18/4/2023 08:56

I wish there was something on the list which can be considered news.

[marcusl2] 18/4/2023 08:52

We are in talks for non-exclusive licenses for SC2811 and Avidimab. Maybe there is someone interested in Immunobody.


4 September 2019
Scancell signs first collaboration agreement for its new platform technology, AvidiMab™, with leading antibody technology company

16 December 2019
Second agreement for AvidiMab™ monoclonal antibody platform signed with Chinese biotech company

20 January 2020 (maybe Seagen)
third agreement signed with a US-based, clinical stage
antibody company to assess monoclonal antibodies (mAbs) targeting tumour-associated glycans (TaGs) including those that have been enhanced with Scancell’s proprietary AvidiMab™ technology.

17 Mar 2022
Fourth agreement with an unnamed ‘major European pharmaceuticals company’.
The new partner, the fourth for the GlyMab platform, wants to ‘further evaluate one of the company's Glymab antibodies for the treatment of cancer’.

24 October 2022
Scancell signs Commercial License Agreement with Genmab up to a maximum of $624 million

[markingtime] 18/4/2023 08:52

I'm sure that she is NOT. Unless they have NDAs with selected parties.

[golcheja] 18/4/2023 08:44

It looks that the same old news is being referenced again and again plus speculation about meetings and disclosure of trial data up to date. Maybe it is the case and in this case the current trial data hopefully is better that what was published before. Let’s hope updated RNS is not too far away.

[marcusl2] 18/4/2023 08:22

I am sure that Lindy is sharing up to date data verbally with the interested parties.

[marcusl2] 18/4/2023 08:17

Scancell says its Head of Clinical Operations to make AACR poster presentation

[markingtime] 18/4/2023 07:59

Another deal today with a 100% share price premium as GSK take out Bellus. Not our sector, of course, but again shows that the big industry players are profiting from the inability of stock markets to properly value treatments under development.Recall that Vulpes recently called the (higher than now) Scancell share price "derisory". At some point the valuation will correct - either in one jump or more gradually.

[plasybryn] 18/4/2023 07:32

Not giving much new away. You have to wait for the presentation.I guess we won't know the impact of relationship building etc. for sometime.

[ivyspivey] 18/4/2023 07:27

Morning
As expected a AACR update this morning

[marcusl2] 17/4/2023 22:18

Roll on Scib-1 plus doublet therapy ipilimumab (Yervoy®) plus nivolumab (Opdivo®) in addition to the cohort who will receive SCIB1 with pembrolizumab (Keytruda®)..

In a Phase 1/2 clinical trial, 14 out of 16 resected patients (89%) survived for more than 5 years following vaccination with SCIB1

Then hopefully the MHRA nod to move over to iScib.

[plasybryn] 17/4/2023 20:54

Fair comment Rigga, but i was just referring to this point in time and where i would expect /even hope the directors will focus their attention. I feel confident we will soon all enjoy the crest of the wave. I have this imagine of Lindy shouting from the roof tops in the not too distant future.

[rigga 1] 17/4/2023 20:00

I've been in this share best part of ten years I certainly don't think this is the hundred meters more like a bloody marathon.

[hn120] 17/4/2023 19:47

Albert Bourla of Pfizer has recently stated that he expects 1 in 3 people to get Cancer, hence why Pfizer are paying 43 BN for Seagen. I wonder what has led him to believe that 1 in 3 people will get Cancer.

[dominiccummings] 17/4/2023 18:49

Could it be whoever started the rumour?

[plasybryn] 17/4/2023 14:31

This is not an event so the Co can satisfy shareholders short termism. No they are focused on communicating the science to influential, potentially long term supporters. Shareholders will be rewarded as a result of course, but this isn't a race to the post. LD and others are more interested in the bigger long term strategic position. Building a knock your socks off situation which won't happen overnight. This could be the first step on such a path. All imo

[markingtime] 17/4/2023 12:08

We'll see.....:-)

[the real lozan] 17/4/2023 12:03

April Spike fodder =
"Looks like a revisit to 25p next stop"
"I look forward to 40p or so by the end of the month."
10 years of trHYPE
10 years of Spiked 'believers'
On and On it goes

[markingtime] 17/4/2023 12:01

....well the reasons for today's weakness is easily answered: someone blew 403,000 shares out first thing at 18.15pWho knows why?.....

[markingtime] 17/4/2023 11:08

Next 48 hours.....

[octopus100] 17/4/2023 11:02

Very disappointing with AACR - run up in price with expectation of very positive update,to support price to next level and public awareness of the company - not going to happen.

When are we expecting next trial updates? Anyone?